ANTONIOLI, ELISABETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.222
EU - Europa 2.719
AS - Asia 412
AF - Africa 11
OC - Oceania 2
SA - Sud America 2
Totale 6.368
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.219
PL - Polonia 1.172
RU - Federazione Russa 634
SE - Svezia 227
IT - Italia 217
IE - Irlanda 192
SG - Singapore 112
CN - Cina 97
DE - Germania 71
HK - Hong Kong 68
UA - Ucraina 67
FI - Finlandia 47
IN - India 42
CH - Svizzera 31
GB - Regno Unito 31
JO - Giordania 27
KR - Corea 21
TR - Turchia 21
VN - Vietnam 17
FR - Francia 15
CI - Costa d'Avorio 11
BE - Belgio 9
AE - Emirati Arabi Uniti 5
CA - Canada 3
EC - Ecuador 2
NL - Olanda 2
AT - Austria 1
AU - Australia 1
BY - Bielorussia 1
LT - Lituania 1
NZ - Nuova Zelanda 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 6.368
Salva come PNG Salva come JPEG
Città #
Warsaw 1.172
Santa Clara 667
Fairfield 429
Chandler 232
Dublin 190
Ashburn 175
Seattle 174
Woodbridge 168
Cambridge 160
Houston 156
Wilmington 145
Jacksonville 126
Singapore 92
Ann Arbor 83
Lawrence 59
Altamura 57
Princeton 47
Beijing 46
Boston 36
New York 36
Hong Kong 33
Mumbai 32
Bern 31
Boardman 31
San Diego 30
Buffalo 25
Moscow 22
Seoul 21
Medford 19
Shanghai 17
Izmir 16
Florence 15
Bremen 14
Dong Ket 13
Salerno 13
Abidjan 11
Andover 11
Falls Church 9
Naples 9
Norwalk 9
Rome 9
Brussels 8
Helsinki 8
Los Angeles 8
Phoenix 8
Milan 7
London 6
Pune 6
Redwood City 6
Abu Dhabi 5
Cagliari 4
Hillsboro 4
Kent 4
Pisa 4
Briosco 3
Cecina 3
Delhi 3
Jena 3
Lomazzo 3
Noicattaro 3
Prato 3
Quartu Sant'Elena 3
Siena 3
Toronto 3
Yubileyny 3
Acton 2
Auburn Hills 2
Augusta 2
Bari 2
Beilngries 2
Dearborn 2
Farra di Soligo 2
Frankfurt Am Main 2
Guayaquil 2
Hangzhou 2
Hebei 2
Hounslow 2
Jiaxing 2
Miles 2
Mountain View 2
Nanchang 2
Palermo 2
Paris 2
Quanzhou 2
Romainville 2
San Mateo 2
Shaoxing 2
Treviso 2
Turin 2
Vinci 2
West Jordan 2
Angeles City 1
Auckland 1
Binche 1
Bratislava 1
Brindisi 1
Buccinasco 1
Canaan 1
Cantagallo 1
Carrara 1
Totale 4.812
Salva come PNG Salva come JPEG
Nome #
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 285
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 279
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis:an international study. 277
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 271
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 267
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis 263
Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. 252
Thrombocytosis and leukocytosis interactions in vascular complications of essential thrombocythemia 230
Nuovi target terapeutici nelle malattie mieloproliferativa croniche Ph negative 222
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. 186
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. 137
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. 129
Leukocytosis and risk stratification assessment in essential thrombocythemia. 129
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. 127
Treatment options for essential thrombocythemia and polycythemia vera 127
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. 124
Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. 123
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. 123
Chemotherapy-related nail toxicity 122
Thrombosis in primary myelofibrosis: incidence and risk factors. 121
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience 120
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. 119
Inconsistencies in the association between the JAL2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases 117
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 114
Risk of second cancers in chronic myeloproliferative neoplasms. 114
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. 113
Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients 113
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis 113
Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. 110
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 108
Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. 108
JAK2V617F allele burden and thrombosis: a direct comparison in Essential Thrombocythemia and Polycythemia Vera 103
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. 100
Mastocitosi: approccio multidisciplinare a una patologia misconoscciuta 97
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. 96
No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia. 94
Risk of second cancers in chronic myeloproliferative neoplasms 93
Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. 90
Aggressive Disease Course of Multiple Myeloma with Concomitant ALK-Negative Anaplastic Large Cell Lymphoma: A Case Report with an Unusual Presentation 88
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. 86
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. 82
Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study 80
Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study 70
Percorsi diagnostici-terapeutici per le neoplasie mieloproliferative nella AOU Careggi 66
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis 66
Ventricular tachyarrhythmias and sudden cardiac death in light-chain amyloidosis: a clash of cardio-toxicities? 61
A multidisciplinary case report of multiple myeloma with renal and cardiac involvement: a look beyond amyloidosis 60
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network 45
Totale 6.420
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.150
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.150
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020752 0 0 0 0 0 147 124 152 117 71 124 17
2020/2021688 78 62 49 67 31 73 26 62 61 84 41 54
2021/2022367 7 58 22 9 11 18 22 20 13 13 76 98
2022/2023974 88 174 47 98 76 157 116 58 89 7 28 36
2023/2024371 16 43 53 18 24 78 8 61 9 20 32 9
2024/20251.602 67 231 169 343 749 43 0 0 0 0 0 0
Totale 6.420